Literature DB >> 18991241

Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage?

Adnan Yilmaz1, Ebru Damadoglu, Cuneyt Salturk, Erdal Okur, Leyla Yagci Tuncer, Semih Halezeroglu.   

Abstract

We aimed to investigate the delays from the first symptom to thoracotomy and to examine whether the delays cause the stage advancement in lung cancer. This prospective study included 138 patients with non-small cell lung carcinoma who underwent thoracotomy. Clinical files of the patients were analyzed and a questionnaire was created to obtain information from the patients. The mean duration values were 81.3 days for the application interval, 61.3 days for the referral interval, 20.3 days for the diagnostic interval, and 21.9 days for the treatment interval. The application interval was longer than 30 days (patient delay) in 50 patients (37.9 %). The mean interval from the first visit to doctor to thoracotomy was 97.2 days. There was a doctor delay in 102 (73.9 %) patients; a referral delay in 83 patients (60.1 %), a diagnostic delay in 47 patients (36.4 %), and a treatment delay in 96 patients (69.6 %). The mean total duration was 176.2 days. Ninety-four patients (71.2 %) had a total delay. Mean total delay was 184.5 days in pathologic stage I, 187.3 days in stage II, 167.7 days in stage IIIA, 142.6 days in stage IIIB, and 150.3 days in stage IV (p>0.05). Delays during the course between the first symptom and thoracotomy in lung cancer patients were a common problem among our patients. Prolonged durations in the application and referral of patients are the most significant cause of delays. Presence of delay or length of delay did not correlate with pathologic tumour stage in this study.

Entities:  

Mesh:

Year:  2008        PMID: 18991241     DOI: 10.3109/2000-1967-236

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


  15 in total

1.  Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study.

Authors:  Hardeep Singh; Kamal Hirani; Himabindu Kadiyala; Olga Rudomiotov; Traber Davis; Myrna M Khan; Terry L Wahls
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes.

Authors:  G Kasymjanova; D Small; V Cohen; R T Jagoe; G Batist; W Sateren; P Ernst; C Pepe; L Sakr; J Agulnik
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

3.  Improving Timeliness of Lung Cancer Diagnosis and Staging Investigations Through Implementation of Standardized Triage Pathways.

Authors:  Monica L L Mullin; Audrey Tran; Breanne Golemiec; Christopher J L Stone; Christine Noseworthy; Nicole O'Callaghan; Christopher M Parker; Geneviève C Digby
Journal:  JCO Oncol Pract       Date:  2020-07-08

Review 4.  Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers.

Authors:  M Elisabeth Del Giudice; Sheila-Mae Young; Emily T Vella; Marla Ash; Praveen Bansal; Andrew Robinson; Roland Skrastins; Yee Ung; Robert Zeldin; Cheryl Levitt
Journal:  Can Fam Physician       Date:  2014-08       Impact factor: 3.275

5.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

Review 6.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

7.  Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.

Authors:  Guanzhong Yan; Ruyong Yao; Dongfang Tang; Tong Qiu; Yi Shen; Wenjie Jiao; Nan Ge; Yunpeng Xuan; Yongjie Wang
Journal:  Med Oncol       Date:  2014-09-06       Impact factor: 3.064

Review 8.  Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Authors:  R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.

Authors:  Gang Chen; Ijeoma Adaku Umelo; Shasha Lv; Erik Teugels; Karel Fostier; Peter Kronenberger; Alex Dewaele; Jan Sadones; Caroline Geers; Jacques De Grève
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

10.  Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases.

Authors:  Yu Zhang; Jie Luo; Rongquan He; Wenting Huang; Zuyun Li; Ping Li; Yiwu Dang; Gang Chen; Shikang Li
Journal:  Onco Targets Ther       Date:  2016-08-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.